CN101995396B - Homogeneous phase multi-index fluorescence/chemiluminescence measuring method and application thereof - Google Patents
Homogeneous phase multi-index fluorescence/chemiluminescence measuring method and application thereof Download PDFInfo
- Publication number
- CN101995396B CN101995396B CN 200910194425 CN200910194425A CN101995396B CN 101995396 B CN101995396 B CN 101995396B CN 200910194425 CN200910194425 CN 200910194425 CN 200910194425 A CN200910194425 A CN 200910194425A CN 101995396 B CN101995396 B CN 101995396B
- Authority
- CN
- China
- Prior art keywords
- labelled antibody
- antibody
- kinds
- fluorescence
- nse
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The invention belongs to the field of blood testing, and relates to a homogeneous phase multi-index fluorescence/chemiluminescence measuring method and application thereof. The method comprises the steps of: fixing a plurality of specificity recognition monoclonal antibodies on a polystyrene microsphere, and reacting with a plurality of labeled antibody cores modified by haptens after combining with carcinoembryonic antigens, cell keratin fragments 19, neuron specificity enolase and other multiple markers; reacting with horse radish peroxidase modified by corresponding hapten antibodies, alkaline phosphatase and quantum dots, and measuring a plurality of markers on the same instrument by combining with detections of chemiluminescence, fluorescence and the like. The method has the advantages of small blood serum consumption, rapid detection time, low diagnosis cost and simple operation, is suitable for detecting a plurality of popularized indexes simultaneously, and can provide auxiliary judgment basis for the early diagnosis of critical illnesses of tumor and the like.
Description
Technical field
The invention belongs to the blood test field, relate to fluorescence/chemiluminescence and detect new technology simultaneously, be specifically related to a kind of many indexs of homogeneous phase fluorescence/chemical luminescent detecting method and uses thereof.Relate in particular to the multiple blood serum designated object fluorescence of major disease such as a kind of tumour/chemiluminescence detection technique simultaneously.
Background technology
Epidemiological study prompting, China not only tumor mortality rate is obvious ascendant trend, and has the characteristics that developing country and developed country are occurred frequently and deposit concurrently, and main cause has 4 points: (1) population astogeny.China is about 49 years old average life span before 50 years, and is more than 70 year old now, and very near developed country's level, aging causes geriatric disease to increase naturally; (2) industrialization development.Along with industrialized progress, influence such as environmental pollution aggravation, cancer morbidity increases; (3) urbanization in rural area is along with the rural area is developed to urbanization, and rhythm of life is more and more nervous, and dietary structure obviously changes, and unhealthy diet increases, and causes cancer morbidity to increase; (4) bad habits and customs such as smoking and bad diet etc.Statistics shows: Chinese annual cancer new cases are about 2,200,000 people, because of the cancer mortality number is 1,600,000 people.Over nearly 20 years, just there is one to die from cancer among every 4-5 the dead person, occupies first of the cause of death.China's tumor incidence in 2006 that treatment and prevention of tumour office of the Ministry of Public Health provides and ten big malignant tumour incidence of disease sequencing display: lung cancer, breast cancer occupy the man respectively, the morbidity of women's malignant tumour is the first, and men and women's mortality of malignant tumors is the highest is lung cancer.It is predicted that to the year two thousand twenty, also will there be 5,500,000 New Development cases of cancers in China, wherein death toll will reach 4,000,000.
At present, the methods for clinical diagnosis of major disease such as lung cancer mainly contains: X ray examination, biopsy, fiberoptic bronchoscopy, CT, MRI and phlegm cytology checking etc.Practice shows, biopsy, and fiberoptic bronchoscopy is traumatic diagnostic mode, and patient body and tissue are had damage to a certain degree, and crowd's limitation is arranged.CT and MRI testing cost are relatively costly, and region hospital does not possess such facility.Phlegm cytology checking is unconventional type inspection, and the patient is often occurring just carrying out such inspection after the tangible symptom, affects early diagnosis opportunity easily adversely.Therefore, the non-invasive early diagnosis new technology that development is fast, expense is low, highly sensitive, specificity is good, particularly serological diagnostic techniques has become the hot research field of rather paying close attention to clinically in recent years.
The achievement in research of modern medicine shows: kinds of tumors mark that comprises in the serum such as carcinomebryonic antigen (CEA), cytokeratin segment 19 (Cyfra21-1) are the outstanding feature thing of early stage non-small cell lung cancerous diagnose; Wherein patients serum Cyfra21-1 value is relevant with the progress degree and the histological classification of lung cancer; It extensively is present in the digestive system cancer of endoderm origin; Also be present in the digest tube tissue of fetal tissues, in normal human serum, also can have trace to exist.Carcinomebryonic antigen (CEA) is a broad spectrum activity tumor markers; Can reflect the existence of kinds of tumors; Practice shows, curative effect judgement, PD, monitoring and the prognosis of colorectal cancer, breast cancer and lung cancer are estimated it is a tumor markers preferably, but its specificity is not strong; Sensitivity is not high, and is not obvious to the early diagnosis of tumor effect.Neuronspecific enolase (NSE) is the outstanding feature thing of early stage ED-SCLC (SCLC) diagnosis; Serum NSE is the peculiar a kind of acid protease of neuron and neuroendocrine cell; The specificity marker thing of neuroendocrine tumor; Like neuroblastoma, thyroid gland medullary substance cancer and ED-SCLC (70% raises), can be used for antidiastole, state of illness monitoring, therapeutic evaluation and recurrence forecast.Above-mentioned tumor markers mainly is present in the patients with lung cancer serum, is applied to major disease diagnosis such as lung cancer respectively.But the lots of clinical data show: single tumor markers exists the not strong drawback of specificity; Particularly the verification and measurement ratio to infantile tumour is not high, often has in the clinical practice adopt that a plurality of marks detect respectively, the method for Conjoint Analysis improves the susceptibility of lesion detection.But; Every kind of mark all needs a kind of radiation or enzyme linked immunological kit; Directly cause deficiencies such as the required serum consumption of these many indexs detection method ubiquities is big, grow detection time, diagnostic fees usefulness height, complicated operation, thereby limited their application clinically.
Summary of the invention
The objective of the invention is in order to overcome prior art detection mark single; Experimental period is long; The serum consumption is big; Diagnostic fees provides a kind of many indexs of homogeneous phase fluorescence/chemical luminescent detecting method with high deficiency, relates in particular to the multiple blood serum designated object fluorescence of major disease such as a kind of tumour/chemiluminescence detection technique simultaneously.
The present invention adopts fixing multiple specific recognition monoclonal antibody on the polystyrene microsphere; Be used for combining, carry out sandwich reaction with the labelled antibody of multiple different hapten transformations then with carcinomebryonic antigen CEA, cytokeratin segment 19Cyfra21-1, neuronspecific enolase NSE and other multiple cancer markers; React with horseradish peroxidase, alkaline phosphatase and the quantum dot that corresponding hapten antibody is modified subsequently, on same instrument, carry out multiple mark in conjunction with detection meanss such as chemiluminescence and fluorescence and measure simultaneously.
Particularly, one kind of multiple blood serum designated object fluorescence of the inventive method/chemiluminescence is detection method simultaneously, can detect the kinds of tumors mark simultaneously.It is characterized in that; Use polystyrene microsphere to combine the coated antibody of kinds of tumors mark as carrier; After corresponding multiple mark in standard solution or the blood serum sample combines, combine with the labelled antibody of preparation respectively, then with anti-digoxin ALP; Labels such as anti-FITC HRP and streptavidin quantum dot or other multiple labels combine, and carry out chemical luminescent detecting at last or directly carry out fluorometric assay.
The inventive method has the advantage that the serum consumption is little, detection time is fast, diagnostic fees is low, many indexs simple to operate, that be fit to promote detect simultaneously, especially can be major disease early diagnosiss such as clinical tumor, and multiple blood serum designated object auxiliary judgment foundation is provided.
The inventive method comprises the steps:
1) coated antibody is attached to preparation carrier antibody compound on the polystyrene microsphere;
2) preparation labelled antibody;
3) the Cyfra21-1 labelled antibody of preparation FITC mark;
4) the biotinylated NSE labelled antibody of preparation;
5) on same instrument, carry out fluorescence/chemical luminescent detecting simultaneously.
Among the present invention, described tumor markers comprises carcinomebryonic antigen (CEA), cytokeratin segment 19 (Cyfra21-1) neuronspecific enolase (NSE).
Among the present invention, the labelled antibody of preparation comprises biotinylation NSE labelled antibody, the CEA labelled antibody of digoxigenin labeled and the Cyfra21-1 labelled antibody of FITC mark or other labelled antibodies.
Among the present invention, utilize EDC to be reflected at and combine tumor marker antibody on the polystyrene microsphere, the polystyrene microsphere antibody complex of its formation is used for the tumor markers detection as carrier;
After above-mentioned antibody complex mixing, add the standard solution or the blood serum sample that contain tumor markers, in 37 ℃ of reaction 1h;
Through washing the labelled antibody that joins preparation in the carrier antibody compound that will be combined with tumor markers, in 37 ℃ of reaction 1h;
Adding ALP modifies anti-digoxin, HRP modifies anti-FITC and quantum dot is modified streptavidin through washing, in 37 ℃ of reaction 1h;
Through washing reaction product is equally divided into 3 groups, each group adds the HRP chemical luminous substrate, the ALP chemical luminous substrate carries out chemical luminescent detecting or directly carries out fluorometric assay.
Among the present invention, determination step carries out on same instrument.
Among the present invention, carry out chemiluminescence and fluorometric assay simultaneously.
Among the present invention, detect three kinds of marks simultaneously,, be suitable for detecting simultaneously mark more than 2 kinds even 3 kinds equally through the suitable adjustment of method.
Among the present invention, use 2 kinds of enzyme labeling things and a kind of fluorescence quantum, but this method is not limited to use more than 2 kinds or is less than 2 kinds of enzyme labeling things and fluorescence quantum more than a kind or a kind, be suitable for detecting simultaneously mark more than 2 kinds even 3 kinds.
Another object of the present invention is to prepare the detection kit that detects the multiple blood serum designated objects of major disease such as tumour simultaneously.
Described detection kit comprises tumor markers labelled antibody and polystyrene microsphere antibody complex;
The preferred tumor markers labelled antibody of the present invention is a biotinylation NSE labelled antibody, the CEA labelled antibody of digoxigenin labeled and the Cyfra21-1 labelled antibody of FITC mark.
For the ease of understanding, below will describe in detail of the present invention through concrete accompanying drawing and embodiment.What need particularly point out is; Instantiation and accompanying drawing only are in order to explain; Obviously those of ordinary skill in the art can explain according to this paper, within the scope of the invention the present invention is made various corrections and change, and these corrections and change are also included in the scope of the present invention.Below in conjunction with accompanying drawing and embodiment the present invention is further specified.
Description of drawings
Fig. 1 is a schematic diagram of the present invention.
Embodiment
(1) combination unlike signal thing is corresponding on the polystyrene microsphere coated antibody, sealing are subsequent use; (2) add standard solution or the serum authentic sample that contains multiple mark standard items; (3) the washing back adds and contains biotinylation NSE labelled antibody, the CEA labelled antibody of digoxigenin labeled and the Cyfra21-1 labelled antibody of FITC mark or multiple other hapten-marked labelled antibody mixed solution; (4) adding ALP modifies anti-digoxin, HRP modifies anti-FITC and quantum dot is modified streptavidin or other hapten-marked tumor markers; (5) be equally divided into three times after, the chemical luminous substrate that adds separately carries out chemical luminescent detecting or directly carries out fluorometric assay.
Embodiment 1
1) coated antibody is attached to preparation carrier antibody compound on the polystyrene microsphere
At first the carboxyl polystyrene microsphere is moved in the centrifuge tube of a 1.5mL, utilize to add imidazoles solution that 100 μ L are dissolved with 1mg EDC after the centrifugal 12000rpm washing of imidazoles solution (0.1M) three times of pH=6.0 in 37 ℃ of activation 30min.Subsequently with the polystyrene microsphere after the imidazoles solution centrifugal washing activation three times, be scattered in 100 μ L imidazoles solution at last after.Add CEA, NSE and Cyfra21-1 coated antibody subsequently, 37 ℃ are reacted 1h down.After the PBSTW washing lotion washing three times, add the PBS solution 200 μ L that contain 2%BSA, 37 ℃ of sealing 1h.After the washing of polystyrene microsphere antibody complex, be kept at the PBS solution for later use that 200 μ L contain 2%BSA.
2) the anti-CEA labelled antibody of preparation digoxin
The 1mg digoxin at first is dispersed in the 400 μ L absolute ethyl alcohols, adds 20 μ L water again, slowly adds the 0.1M sodium periodate solution of 45 μ L, dissolves afterreaction 30mi n fully to digoxin, and the ethylene glycol solution that adds 35 μ L 1M subsequently reacted 5 minutes, preserved subsequent use.
The anti-CEA labelled antibody of 300 μ L adds 200 μ L water, transfers pH to 9.5 with 5% solution of potassium carbonate, adds the digoxin solution 20 μ L reaction 1h after the above-mentioned oxidation; Add 6mg sodium borohydride reaction 4h subsequently; Regulate pH to 6.5 with 1M formic acid, regulate pH to 9.5 with ammoniacal liquor behind the reaction 1h, after the dialysed overnight; It is for use to be concentrated into 150 μ L, uses ultraviolet spectrophotometry to record protein concentration and is 1.63mg/mL.
3) the Cyfra21-1 labelled antibody of preparation FITC mark.
Concentrate 150 μ LCyfra21-1 antibody to 90 μ L; In the 0.1M sodium carbonate/bicarbonate solution of pH9.2; The 0.1M sodium carbonate sodium bicarbonate solution that adds the fluorescein isothiocynate (FITC) of 10 μ L subsequently, the 12h that in 0.1M sodium carbonate/bicarbonate solution, dialyses utilizes PBS solution dialysis 12h again; Concentrated solution to 150 μ L is for use subsequently, uses ultraviolet spectrophotometry to record protein concentration and is 3.45mg/mL.
4) the biotinylated NSE labelled antibody of preparation
Behind 100 μ L NSE labelled antibodies removal impurity; Be dissolved among the 100 μ LPBS; Add NHSization biotin (N-hydroxy-succinamide biotin) that 5 μ L0.1M are dissolved in DMF in 4 ℃ of reaction 2.5h; Utilize the PBS dialysed overnight then, it is for use to be concentrated into 100 μ L, uses ultraviolet spectrophotometry to record protein concentration and is 1.39mg/mL.
5) chemiluminescence and fluoroscopic examination step
After 50 μ L sealing polystyrene microsphere good and that be combined with CEA, NSE and Cyfra21-1 coated antibody mixes, centrifugal or cross film and remove supernatant.Add 100 μ L subsequently and contain standard solution or the true blood serum sample of CEA, NSE and Cyfra21-1,37 ℃ of reaction 1h down.Behind the 200 μ LPBSTW solution washings three times; Add 100 μ L and contain the 2%BSA-PBS solution of Cyfra21-1 labelled antibody (3.45ug/ hole) of CEA labelled antibody (0.815ug/ hole) and the FITC mark of biotinylation NSE labelled antibody (0.5ug/ hole), digoxigenin labeled, 37 ℃ of reaction 1h.After washing three times, add 100 μ L and contain anti-digoxin modification ALP (1: 1000), anti-FITC modification HRP (1: 1000) and streptavidin modification quantum dot (1: 200), in 37 ℃ of reaction 1h.After the washing, be divided into three parts, add 50 μ LPBS fluorometric assaies, or 100 μ LHRP chemical luminous substrates or ALP chemical luminous substrate, on same instrument, carry out fluorescence/chemical luminescent detecting simultaneously.
Claims (6)
1. many indexs of homogeneous phase fluorescence/chemical luminescent detecting method; It is characterized in that, on same instrument, carry out chemiluminescence and fluorometric assay simultaneously, check 3 kinds of marks simultaneously; Comprise the coated antibody that combines the kinds of tumors mark with polystyrene microsphere as carrier; After corresponding multiple mark in standard solution or the blood serum sample combines, combine with the labelled antibody of preparation respectively, then with anti-digoxin ALP; After the quantum dot-labeled thing of anti-FITC HRP and streptavidin combines, carry out chemical luminescent detecting or directly carry out the fluorometric assay blood serum designated object;
Described tumor markers is carcinomebryonic antigen CEA, cytokeratin segment 19Cyfra21-1 and neuronspecific enolase NSE;
The labelled antibody of described preparation is a biotinylation NSE labelled antibody, the CEA labelled antibody of digoxigenin labeled and the Cyfra21-1 labelled antibody of FITC mark.
2. by many indexs of the described homogeneous phase of claim 1 fluorescence/chemical luminescent detecting method, it is characterized in that it comprises the steps:
1) coated antibody is attached to preparation carrier antibody compound on the polystyrene microsphere;
2) the CEA labelled antibody of preparation digoxigenin labeled;
3) the Cyfra21-1 labelled antibody of preparation FITC mark;
4) the biotinylated NSE labelled antibody of preparation;
5) on same instrument, carry out fluorescence/chemical luminescent detecting simultaneously.
3. method according to claim 2 is characterized in that, after the antibody complex mixing with step 1), adds the standard solution or the blood serum sample that contain tumor markers CEA, Cyfra21-1, NSE, in 37 ℃ of reaction 1h;
Carrier antibody compound washing with being combined with said tumor markers joins step 2,3,4) the biotinylation NSE labelled antibody processed, the CEA labelled antibody of digoxigenin labeled and the Cyfra21-1 labelled antibody of FITC mark react 1h in 37 ℃;
After the reaction, through washing, adding ALP modifies anti-digoxin, HRP modifies anti-FITC and quantum dot is modified streptavidin, in 37 ℃ of reaction 1h;
Through washing reaction product is equally divided into 3 groups, each group adds the HRP chemical luminous substrate, the ALP chemical luminous substrate carries out chemical luminescent detecting or directly carries out fluorometric assay.
4. method according to claim 1 is characterized in that, this method detects 3 kinds of marks simultaneously, or detects mark more than 2 kinds or 3 kinds simultaneously.
5. method according to claim 1 is characterized in that this method uses 2 kinds of enzyme labeling things and a kind of fluorescence quantum, or uses more than 2 kinds or be less than 2 kinds of enzyme labeling things or fluorescence quantum more than a kind or a kind.
6. a kit that detects the multiple blood serum designated object of tumour is characterized in that, it comprises tumor markers labelled antibody and polystyrene microsphere antibody complex and enzyme labeling thing and fluorescence quantum; Described tumor markers labelled antibody is a biotinylation NSE labelled antibody, the CEA labelled antibody of digoxigenin labeled and the Cyfra21-1 labelled antibody of FITC mark; Wherein, the determination step that uses described kit to detect the multiple blood serum designated object of tumour carries out chemiluminescence and fluorometric assay simultaneously on same instrument, check 3 kinds of marks simultaneously.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200910194425 CN101995396B (en) | 2009-08-21 | 2009-08-21 | Homogeneous phase multi-index fluorescence/chemiluminescence measuring method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200910194425 CN101995396B (en) | 2009-08-21 | 2009-08-21 | Homogeneous phase multi-index fluorescence/chemiluminescence measuring method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101995396A CN101995396A (en) | 2011-03-30 |
| CN101995396B true CN101995396B (en) | 2012-12-12 |
Family
ID=43785846
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200910194425 Expired - Fee Related CN101995396B (en) | 2009-08-21 | 2009-08-21 | Homogeneous phase multi-index fluorescence/chemiluminescence measuring method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101995396B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104569431B (en) * | 2015-01-04 | 2017-01-11 | 深圳市艾瑞生物科技有限公司 | Homogenous phase fluorescence immunoassay reagent group for fast and quantitatively detecting troponin I and preparation method thereof |
| CN104569409B (en) * | 2015-01-04 | 2017-01-11 | 深圳市艾瑞生物科技有限公司 | Homogenous phase fluorescence immunoassay reagent group for fast and quantitatively detecting myeloperoxidase and preparation method thereof |
| CN104569374B (en) * | 2015-01-04 | 2017-01-11 | 深圳市艾瑞生物科技有限公司 | Homogeneous fluorescence immunoassay-based reagent group capable of rapidly and quantitatively detecting C-reactive proteins and preparation method of homogeneous fluorescence immunoassay-based reagent group |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101144815A (en) * | 2006-09-13 | 2008-03-19 | 广州市达瑞抗体工程技术有限公司 | Preparation method of liquid phase protein chip |
| CN101221182A (en) * | 2007-01-08 | 2008-07-16 | 山东司马特生物芯片有限公司 | Novel method for blood serum tumor series diagnosis by fluorescent protein chip |
-
2009
- 2009-08-21 CN CN 200910194425 patent/CN101995396B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101144815A (en) * | 2006-09-13 | 2008-03-19 | 广州市达瑞抗体工程技术有限公司 | Preparation method of liquid phase protein chip |
| CN101221182A (en) * | 2007-01-08 | 2008-07-16 | 山东司马特生物芯片有限公司 | Novel method for blood serum tumor series diagnosis by fluorescent protein chip |
Non-Patent Citations (3)
| Title |
|---|
| 侯惠仁等.癌胚抗原（CEA）酶联免疫分析试剂盒的研制.《同位素》.2001,第14卷(第3-4期),227-229. * |
| 孙来玉.测定癌胚抗原免疫芯片技术的研究.《中国计量学院学报》.2006,第17卷(第2期),107-110. * |
| 林海龙等.肿瘤标记物蛋白芯片对肺癌的诊断价值.《第三军医大学学报》.2005,第27卷(第15期),1591-1592. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101995396A (en) | 2011-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6294349B1 (en) | Method of diagnosing and monitoring malignant breast carcinomas | |
| CN102625914B (en) | The method of detection carcinoma of urinary bladder or carcinoma of urinary bladder risk | |
| US20060211059A1 (en) | Methods of improving screening, diagnosis and staging of prostate cancer using serum testosterone | |
| Liu et al. | Multiple tumor marker protein chip detection system in diagnosis of pancreatic cancer | |
| CN105316405A (en) | Markers for detection of gastric cancer | |
| CN103529207A (en) | Combined device for rapidly and quantitatively detecting multiple tumor markers | |
| CN109061165A (en) | A kind of immune chromatography test paper, detection method and the application of nipple discharge CEA detection | |
| US9671413B2 (en) | Prostate cancer point of care diagnostics | |
| CN104316685A (en) | Diacetyl spermine detection kit and preparation method and application thereof | |
| CN112345755A (en) | Biomarker of breast cancer and application thereof | |
| CN109557311A (en) | The testing product and its application of diagnosis of colorectal carcinoma marker and colorectal cancer | |
| US20120295288A1 (en) | Serological marker for detecting pancreatic cancer and a method for using the serological marker | |
| CN110187109A (en) | A kind of autoantibody joint-detection ELISA kit for Grades of Gastric Cardia Adenocarcinoma early screening | |
| CN113607948A (en) | Application of detecting content of Glypican-1 protein in serum in evaluating pancreatic cancer occurrence development and stage judgment | |
| CN101995396B (en) | Homogeneous phase multi-index fluorescence/chemiluminescence measuring method and application thereof | |
| CN109507426A (en) | Prostate cancer diagnosis, classification or prognostic marker, detection reagent or kit, system and its application | |
| US20220214365A1 (en) | Methods of Detecting Anti-folic acid Antibodies and Uses Thereof | |
| CN105717147A (en) | Model for predicating lung cancer risks for people suffering from pulmonary nodules among China urban population on basis of CT (computed tomography) images and biomarker spectrums | |
| CN102375057A (en) | Method for simultaneously detecting a plurality of serum markers by homogeneous fluorescence | |
| CN101493463B (en) | Stomach cancer diagnosis reagent and uses thereof | |
| CN104076151A (en) | Kit for early diagnosis of glioma | |
| WO2013120394A1 (en) | Kit for detection or diagnosis of prostate cancer | |
| CN105259348B (en) | A kind of secreting type Sema4C albumen and its application | |
| CN107144688B (en) | CD19 positive excretion bodies are as application of the molecular labeling in preparing tumor diagnosis kit and kit | |
| CN109507425A (en) | Carcinoma of prostate based on the extracellular vesica of thermophoresis recurs monitoring system and method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20121212 Termination date: 20150821 |
|
| EXPY | Termination of patent right or utility model |